Catalog No.: PC-24437Not For Human Use, Lab Use Only.
CHK-336 is a potent and selective, orally active, liver-targeted inhibitor of lactate dehydrogenase (LDH) with IC50 of 0.4 nM in human enzyme assays, and IC50 of 80-131 nM in cryopreserved hepatocyte assays across species.
CHK-336 is a potent and selective, orally active, liver-targeted inhibitor of lactate dehydrogenase (LDH) with IC50 of 0.4 nM in human enzyme assays, and IC50 of 80-131 nM in cryopreserved hepatocyte assays across species. CHK-336 demonstrated a favourable liver-distribution profile in mice, rats, and monkeys. CHK-336 inhibited conversion of 13C2-glycolate to 13C2-oxalate in a dose-dependent manner in rat pharmacodynamic models. CHK-336 produced robust and dose-dependent reductions in urinary oxalate to the normal range in primary hyperoxaluria 1 (PH1) mouse model, also induced a significant reduction in urinary oxalate in a PH2 mouse model.
